EU GMP Chapter 3 extends compliance beyond cleanrooms. It requires a risk-based approach to facility design driven by Quality Risk Management to prevent cross-contamination, including the use of dedicated facilities where needed. The chapter also highlights the critical role of printed packaging materials and the importance of site design details, all working together to protect patient safety.

EU GMP Chapter 2 sets out the core personnel requirements that every pharmaceutical manufacturer must meet, and many organisations still misunderstand them. In this article, Clear S.r.l.S.B. explains the five most important EU GMP personnel principles, including the ultimate quality responsibility of senior management, the legal accountability of the Qualified Person (QP), the required independence between Production and Quality Control, the mandatory scope of GMP training.

EU GMP Chapter 1 transforms the Pharmaceutical Quality System (PQS) from a compliance checklist into a strategic business asset. This article explores 4 core principles: placing ultimate responsibility in the C-Suite, digging deeper than “human error,” extending oversight across the full product lifecycle, and mandating continual improvement. Learn how to evolve your PQS from a cost center into a driver of resilience and operational excellence.

EMA GACP Revision 1 modernizes Good Agricultural and Collection Practice for today’s medical cannabis operations, with a specific focus on indoor cultivation controls. This article explains what GACP is, why it is the starting point for pharmaceutical supply chains, and how it connects to GMP expectations. It highlights the most relevant updates for cultivators, including Annex 1 requirements for controlled environments, the need to define Critical Quality Attributes.